GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Applied Biosciences Corp (OTCPK:APPB) » Definitions » Cash Flow from Financing

Applied Biosciences (Applied Biosciences) Cash Flow from Financing : $0.88 Mil (TTM As of Dec. 2019)


View and export this data going back to 2015. Start your Free Trial

What is Applied Biosciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2019, Applied Biosciences paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Applied Biosciences spent $0.00 Mil on financial activities for the three months ended in Dec. 2019.


Applied Biosciences Cash Flow from Financing Historical Data

The historical data trend for Applied Biosciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Biosciences Cash Flow from Financing Chart

Applied Biosciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18
Cash Flow from Financing
0.01 0.01 0.03 1.13 0.70

Applied Biosciences Quarterly Data
Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 0.09 0.39 0.40 -

Applied Biosciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Applied Biosciences's Cash from Financing for the fiscal year that ended in Mar. 2018 is calculated as:

Applied Biosciences's Cash from Financing for the quarter that ended in Dec. 2019 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied Biosciences  (OTCPK:APPB) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Applied Biosciences's issuance of stock for the three months ended in Dec. 2019 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Applied Biosciences's repurchase of stock for the three months ended in Dec. 2019 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Applied Biosciences's net issuance of debt for the three months ended in Dec. 2019 was $0.00 Mil. Applied Biosciences received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Applied Biosciences's net issuance of preferred for the three months ended in Dec. 2019 was $0.00 Mil. Applied Biosciences paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Applied Biosciences's cash flow for dividends for the three months ended in Dec. 2019 was $0.00 Mil. Applied Biosciences received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Applied Biosciences's other financing for the three months ended in Dec. 2019 was $0.00 Mil. Applied Biosciences received $0.00 Mil on other financial activities.


Applied Biosciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Applied Biosciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied Biosciences (Applied Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
320 Park Avenue, 18th Floor, New York, NY, USA, 10022
Applied Biosciences Corp is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. The company also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to its customers.
Executives
Michael Beaubaire director 9701 WILSHIRE BLVD. SUITE 1000 BEVERLY HILLS CA 90212
John Robert Brady 10 percent owner 9701 WILSHIRE BLVD., SUITE 1000 BEVERLY HILLS CA 90212
Raymond W. Urbanski director, officer: Chief Executive Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Scott B Stevens director 9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Chris Bridges director, officer: President 9701 WILSHIRE BLVD., SUITE 1000 BEVERLY HILLS CA 90212
John James Southard officer: Secretary and Treasurer 9701 WILSHIRE BLVD., SUITE 1000 BEVERLY HILLS CA 90212
Sbs Family Trust 10 percent owner 521 RXR PLAZA EAST TOWER ? SUITE 521 UNIONDALE NY 11556